Pesquisa | Biblioteca Virtual em Saúde

1.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva, Aleksandra P; Wang, James; Spektor, Tanya M; Bitran, Jacob D; Lutzky, Jose; Tabbara, Imad A; Ye, Joseph Z; Ailawadhi, Sikander; Stampleman, Laura V; Steis, Ronald G; Moezi, Mehdi M; Swift, Regina A; Maluso, Tina M; Udd, Kyle A; Eshaghian, Shahrooz; Nassir, Youram; Berenson, James R.

Support Care Cancer ; 25(10): 3217-3224, 2017 10.

Artigo em Inglês | MEDLINE | ID: mdl-28455546

2.

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.

Daniely, David; Forouzan, Eli; Spektor, Tanya M; Cohen, Alexa; Bitran, Jacob D; Chen, Gigi; Moezi, Mehdi M; Bessudo, Alberto; Hrom, John; Eshaghian, Shahrooz; Swift, Regina A; Eades, Benjamin M; Kim, Clara; Lim, Stephen; Berenson, James R.

Exp Hematol ; 111: 79-86, 2022 07.

Artigo em Inglês | MEDLINE | ID: mdl-35417741

3.

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Lazarus, Hillard M; Zhang, Mei-Jie; Carreras, Jeanette; Hayes-Lattin, Brandon M; Ataergin, Asli Selmin; Bitran, Jacob D; Bolwell, Brian J; Freytes, César O; Gale, Robert Peter; Goldstein, Steven C; Hale, Gregory A; Inwards, David J; Klumpp, Thomas R; Marks, David I; Maziarz, Richard T; McCarthy, Philip L; Pavlovsky, Santiago; Rizzo, J Douglas; Shea, Thomas C; Schouten, Harry C; Slavin, Shimon; Winter, Jane N; van Besien, Koen; Vose, Julie M; Hari, Parameswaran N.

Biol Blood Marrow Transplant ; 16(1): 35-45, 2010 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-20053330

4.

Reducing Unwarranted Oncology Care Variation Across a Clinically Integrated Network: A Collaborative Physician Engagement Strategy.

Richards, Jon M; Burgon, Trever B; Tamondong-Lachica, Diana; Bitran, Jacob D; Liangco, Wilfredo L; Paculdo, David R; Peabody, John W.

J Oncol Pract ; 15(12): e1076-e1084, 2019 12.

Artigo em Inglês | MEDLINE | ID: mdl-31573829

5.

Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).

Lazarus, Hillard M; Carreras, Jeanette; Boudreau, Christian; Loberiza, Fausto R; Armitage, James O; Bolwell, Brian J; Freytes, César O; Gale, Robert Peter; Gibson, John; Hale, Gregory A; Inwards, David J; LeMaistre, Charles F; Maharaj, Dipnarine; Marks, David I; Miller, Alan M; Pavlovsky, Santiago; Schouten, Harry C; van Besien, Koen; Vose, Julie M; Bitran, Jacob D; Khouri, Issa F; McCarthy, Philip L; Yu, Hongmei; Rowlings, Philip; Serna, Derek S; Horowitz, Mary M; Rizzo, J Douglas.

Biol Blood Marrow Transplant ; 14(12): 1323-33, 2008 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-19041053

6.

Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.

Nabhan, Chadi; Ragam, Avanthi; Samuels, Brian; Milton, Daniel T; Prasad, Leela; Hooberman, Arthur; Hartsell, William; Anthony, Andi; Weisman, Robert; Bitran, Jacob D.

Clin Colorectal Cancer ; 6(6): 436-41, 2007 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-17531107

7.

Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.

Meyer, Andrew; Cygan, Peter; Tolzien, Kathy; Galvez, Angel G; Bitran, Jacob D; Lestingi, Timothy M; Nabhan, Chadi.

Clin Genitourin Cancer ; 12(2): 100-5, 2014 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-24169494

8.

Erlotinib in lung cancer.

Nabhan, Chadi; Bitran, Jacob D.

N Engl J Med ; 353(16): 1739-41; author reply 1739-41, 2005 Oct 20.

Artigo em Inglês | MEDLINE | ID: mdl-16236747

9.

Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?

Nabhan, Chadi; Bitran, Jacob D.

J Clin Oncol ; 23(31): 8126-7; author reply 8127, 2005 Nov 01.

Artigo em Inglês | MEDLINE | ID: mdl-16258116

10.

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy.

Nabhan, Chadi; Meyer, Andrew; Tolzien, Kathy; Bitran, Jacob D; Lestingi, Timothy M.

Avicenna J Med ; 1(1): 12-7, 2011 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-23210004

11.

Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.

Nabhan, Chadi; Davis, Nancy; Bitran, Jacob D; Galvez, Angel; Fried, Walter; Tolzien, Kathy; Foss, Susan; Dewey, Wendy M; Venugopal, Parameswaran.

Cancer ; 117(7): 1490-7, 2011 Apr 01.

Artigo em Inglês | MEDLINE | ID: mdl-21425150

12.

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

Nabhan, Chadi; Lestingi, Timothy M; Galvez, Angel; Tolzien, Kathy; Kelby, Susan K; Tsarwhas, Dean; Newman, Steven; Bitran, Jacob D.

Urology ; 74(3): 665-71, 2009 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-19616281

13.

Disclosing the cancer diagnosis:the myth and the truth.

Nabhan, Chadi; Bitran, Jacob D; Moore, Clint.

J Clin Oncol ; 29(6): e145-6; author reply e147, 2011 Feb 20.

Artigo em Inglês | MEDLINE | ID: mdl-21135280

14.

High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma.

Bitran, Jacob D; Klein, Leonard; Link, Doreen; Kosirog-Glowacki, Jane; Stewart, Cynthia; Raack, David; Sheahan, Pat; Lisowski, Josephine; Rowen, Josie.

Biol Blood Marrow Transplant ; 9(6): 383-8, 2003 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-12813446

15.

Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?

Nabhan, Chadi; Bitran, Jacob D.

J Clin Oncol ; 24(18): 2967-8; author reply 2968-9, 2006 Jun 20.

Artigo em Inglês | MEDLINE | ID: mdl-16782938

Biblioteca Virtual em Saúde

Saúde Pública Brasil

Sua seleção (0)

Formato de exportação:

Exportar:

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

Reducing Unwarranted Oncology Care Variation Across a Clinically Integrated Network: A Collaborative Physician Engagement Strategy.

Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).

Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.

Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.

Erlotinib in lung cancer.

Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy.

Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

Disclosing the cancer diagnosis:the myth and the truth.

High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma.

Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?